GE Healthcare’s cardiac spectral CT has received FDA 510(k) clearance, the company announced.
GE Healthcare’s cardiac spectral CT has received FDA 510(k) clearance, the company announced. The Discovery CT750 HD Freedom Edition addresses challenges in cardiac imaging such as coronary motion, calcium booming, plaque composition and accurate myocardial perfusion, the company said.
The system provides the following features: Motion Freedom with motion correction via SnapShot Freeze, which helps reduce cardiac motion by detecting vessel motion and velocity to determine the position and correct the effects of motion; Calcium Freedom with enhanced coronary visualization using Gemstone Spectra Imaging Cardiac; and Horizon Free, which provides plaque material composition assessment and accurate perfusion calculations.
The HD Freedom Edition’s first U.S. installation was at the University of Washington, Seattle, and is available in about two dozen locations in Europe and Japan, where physicians are using SnapShot Freeze and GSI Cardiac in routine practice for coronary evaluation.
According to GE, the system leads the industry in cardiac CT spatial resolution at 18.2 lp/cm, which helps physicians accurately quantify stenoses in coronary vessels by displaying reduction in calcium blooming compared to standard resolution.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.